Frontiers in Immunology (Feb 2024)

Pan-immune inflammation value as a prognostic biomarker for cancer patients treated with immune checkpoint inhibitors

  • Tianrui Kuang,
  • Tianrui Kuang,
  • Zhendong Qiu,
  • Zhendong Qiu,
  • Kunpeng Wang,
  • Kunpeng Wang,
  • Lilong Zhang,
  • Lilong Zhang,
  • Keshuai Dong,
  • Keshuai Dong,
  • Weixing Wang,
  • Weixing Wang

DOI
https://doi.org/10.3389/fimmu.2024.1326083
Journal volume & issue
Vol. 15

Abstract

Read online

BackgroundImmune checkpoint inhibitors (ICIs) represent a paradigm shift in the development of cancer therapy. However, the improved efficacy of ICIs remains to be further investigated. We conducted a systematic review and meta-analysis to evaluate the pan-immunoinflammatory value (PIV) and PILE score used to predict response to ICI therapy.MethodsWe searched selected databases for studies on pan-immune inflammation values and their association with outcomes of treatment with immune checkpoint inhibitors. We used hazard ratios (HRS) and 95% confidence intervals (CI) to summarize survival outcomes. All data analyses were performed using STATA 15.0.Results7 studies comprising 982 patients were included in the meta-analysis. The pooled results showed that higher PIV was significantly associated with shorter overall survival OS (HR = 1.895, 95%CI: 1.548-2.318) and progression-free survival (PFS) (HR = 1.582, 95%CI: 1.324-1.890). Subgroup analyses also confirmed the reliability of the results.ConclusionsHigh PIV and PILE metrics are associated with lower survival in cancer patients receiving ICIs.

Keywords